Oncology
Our specialist oncology resources cover the latest guidelines and scientific updates to support your clinical practice, from assessing patient risk of disease recurrence to identifying unmet needs.
Medical conditions
Bladder cancer
Expert congress highlights and recent advances
Breast cancer
Expert podcast and congress highlights
Haematological and Bone Marrow Cancers
Containing relevant Learning Zones, guidelines, trials and news.
Leukemia
Latest news, insights, and guideline updates
Lymphoma
Earn CME credit, plus expert congress highlights
Non-small-cell lung cancer
Latest insights and spotlight articles
Ovarian cancer
Latest news, insights, and guideline updates
Prostate Cancer Nexus
Congress coverage and expert podcasts
Thyroid cancer
Latest news, insights, and guideline updates
Learning zones and other resources
Abemaciclib: a newcomer in the treatment of HR+/HER2− early breast cancer
Abemaciclib, a CDK4/6 inhibitor, is the first adjuvant in 16 years to be added to endocrine therapy for HR+/HER2− early breast cancer and the first of its class to receive FDA and EMA approval for this indication.
Can telemedicine palliate patients with NSCLC?
Presented by Dr Joseph Greer (Massachusetts General Hospital Cancer Center, USA) at ASCO 2024, read outcome data from the REACH PC trial for comparing the effectiveness of early palliative care delivered through video with in-person care for patients with advanced NSCLC
Osimertinib for EGFR-mutated NSCLC – LAURA trial
Presented by Dr Suresh S Ramalingam (Winship Cancer Institute of Emory University, USA) at ASCO 2024, read LAURA outcome data for osimertinib for managing unresectable stage 3 EGFR-mutated NSCLC without progression.
ASCO 2024 A high-level overview
From ASCO 2024, read Dr Ben Gallarda’s overview of ASCO’s commitment to palliative care, artificial intelligence, and coordination with organizations.
Symposium on refractory multiple myeloma, COMy 2023
Watch our expert panel discussion on the management of relapsed and refractory multiple myeloma (RRMM) in older and frail adults.
How can poor-quality clinical trials impact clinical decision-making?
Explore why a cautious approach is warranted when interpreting trial results.
of interest
are looking at
saved
next event
